ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

(2020) Wenhua Liang et al.   LANCET ONCOLOGY

Caring for patients with pain during the COVID ‐19 pandemic: consensus recommendations from an international expert panel

(2020) H. Shanthanna et al.   ANAESTHESIA

Managing COVID-19 in the oncology clinic and avoiding the distraction effect

(2020) F. Cortiula et al.   ANNALS OF ONCOLOGY

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

(2020) L. Zhang et al.   ANNALS OF ONCOLOGY

Whose life to save? Scarce resources allocation in the COVID-19 outbreak

(2020) Chiara Mannelli   JOURNAL OF MEDICAL ETHICS

Cancer guidelines during the COVID-19 pandemic

(2020) Talha Khan Burki   LANCET ONCOLOGY

Caring for patients with cancer in the COVID-19 era

(2020) Joris van de Haar et al.   NATURE MEDICINE

Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic

(2020) Timothy P. Hanna et al.   Nature Reviews Clinical Oncology

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

(2020) Tao Wang et al.   Lancet Haematology

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

(2019) Andrea Wang-Gillam et al.   EUROPEAN JOURNAL OF CANCER

Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery

(2018) Douglas S. Swords et al.   SURGERY

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) M. Ducreux et al.   ANNALS OF ONCOLOGY

Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy

(2015) Lilian Schwarz et al.   ANNALS OF SURGICAL ONCOLOGY

Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

(2015) Jun Yu et al.   GUT

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

(2014) Helmut Oettle et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

(2014) Juan W. Valle et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE